Group
Companies
History
Business model
Mission and vision
Corporate values
Commitment to sport
Research
Pharmaceutical Research
Sucrosomial Technology
Cetylated Fatty Acids
Quality and certifications
Brands
PharmaNutra
Alesco
Akern
Investor
INVESTOR RELATIONS
Stock performance
Share capital and Shareholders
Shares study and research
Broker
Financial statements
Presentations
Corporate events
Company presentation
Notice of meetings
SDIR
AIM admission document
MTA prospectus
PRESS
Press releases
Press review
Governance
Code of Ethics
231 Model
Board of Directors and Committees
Company documents
Internal dealing
Shareholders’ meeting
Statutory auditors and Audit firm
Sharholders Agreements
Sustainability
News
Science
Corporate
Events
Social commitment
Careers
Work with us
Job offers
Job application
Group
Companies
History
Business model
Mission and vision
Corporate values
Commitment to sport
Research
Pharmaceutical Research
Sucrosomial Technology
Cetylated Fatty Acids
Quality and certifications
Brands
PharmaNutra
Alesco
Akern
Investor
INVESTOR RELATIONS
Stock performance
Share capital and Shareholders
Shares study and research
Broker
Financial statements
Presentations
Corporate events
Company presentation
Notice of meetings
SDIR
AIM admission document
MTA prospectus
PRESS
Press releases
Press review
Governance
Code of Ethics
231 Model
Board of Directors and Committees
Company documents
Internal dealing
Shareholders’ meeting
Statutory auditors and Audit firm
Sharholders Agreements
Sustainability
News
Science
Corporate
Events
Social commitment
Careers
Work with us
Job offers
Job application
it
en
Category:
22 June 2024
Internal dealing communication
18 June 2024
THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO
13 June 2024
A NEW STUDY HIGHLIGHTS THE EFFICACY, SUPERIORITY AND IMPROVED TOLERABILITY OF SIDERAL® COMPARED TO CONVENTIONAL IRON SUPPLEMENT TREATMENTS
12 June 2024
INITIATION OF SHARE BUY-BACK PROGRAM
29 May 2024
ASSUNZIONE QUALIFICA DI PMI
13 May 2024
PHARMANUTRA S.P.A. THE BOD APPROVES THE INTERIM MANAGEMENT REPORT AS AT 31 MARCH2024 AND THE 2023 SUSTAINABILITY REPORT
15 April 2024
THE MERGER BY INCORPORATION INTO PHARMANUTRA S.P.A. OF JUNIA PHARMA S.R.L. AND ALESCO S.R.L. HAS BEEN APPROVED
15 March 2024
PHARMANUTRA S.P.A.: THE BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31 DECEMBER 2023
26 February 2024
Approval of the merger plan
11 January 2024
EURO 100 MILLION IN REVENUE REACHED IN THE YEAR OF ITS 20TH ANNIVERSARY SINCE ESTABLISHMENT
08 January 2024
LOSS OF SME STATUS
21 December 2023
PUBLICATION OF THE 2024 CORPORATE EVENTS CALENDAR
1
2
…
18
>